<SEC-DOCUMENT>0001558370-25-000105.txt : 20250110
<SEC-HEADER>0001558370-25-000105.hdr.sgml : 20250110
<ACCEPTANCE-DATETIME>20250110092751
ACCESSION NUMBER:		0001558370-25-000105
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		15
CONFORMED PERIOD OF REPORT:	20250106
ITEM INFORMATION:		Results of Operations and Financial Condition
ITEM INFORMATION:		Cost Associated with Exit or Disposal Activities
ITEM INFORMATION:		Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
ITEM INFORMATION:		Regulation FD Disclosure
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20250110
DATE AS OF CHANGE:		20250110

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Y-mAbs Therapeutics, Inc.
		CENTRAL INDEX KEY:			0001722964
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		IRS NUMBER:				474619612
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-38650
		FILM NUMBER:		25520824

	BUSINESS ADDRESS:	
		STREET 1:		230 PARK AVENUE
		STREET 2:		SUITE 3350
		CITY:			NEW YORK
		STATE:			NY
		ZIP:			10169
		BUSINESS PHONE:		212-847-9841

	MAIL ADDRESS:	
		STREET 1:		230 PARK AVENUE
		STREET 2:		SUITE 3350
		CITY:			NEW YORK
		STATE:			NY
		ZIP:			10169
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>ymab-20250106x8k.htm
<DESCRIPTION>8-K
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<!-- iXBRL document created with: Toppan Merrill Bridge iXBRL 10.9.0.3 -->
<!-- Based on: iXBRL 1.1 -->
<!-- Created on: 1/10/2025 12:19:56 PM -->
<!-- iXBRL Library version: 1.0.9062.16423 -->
<!-- iXBRL Service Job ID: 619d6db8-6d5e-4970-8fa4-c28f541a20ce -->
<html xmlns:dei="http://xbrl.sec.gov/dei/2024" xmlns:ymab="http://www.ymabs.com/20250106" xmlns="http://www.w3.org/1999/xhtml" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xs="http://www.w3.org/2001/XMLSchema-instance" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2022-02-16" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:xbrli="http://www.xbrl.org/2003/instance"><head><meta http-equiv="content-type" content="text/html"/><title></title></head><body><div style="margin-top:30pt;"></div><div style="display:none;"><ix:header><ix:hidden><ix:nonNumeric contextRef="Duration_1_6_2025_To_1_6_2025_rbdgIz0CSUSvSHbyAAhdRA" name="dei:EntityCentralIndexKey" id="Tc__BPge1uGVEWUsqnr_vfcEQ_2_1">0001722964</ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_6_2025_To_1_6_2025_rbdgIz0CSUSvSHbyAAhdRA" name="dei:AmendmentFlag" id="Tc_49xjKJKJREyvrnlv4PNT0g_3_1">false</ix:nonNumeric></ix:hidden><ix:references><link:schemaRef xlink:href="ymab-20250106.xsd" xlink:type="simple"/></ix:references><ix:resources><xbrli:context id="Duration_1_6_2025_To_1_6_2025_rbdgIz0CSUSvSHbyAAhdRA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001722964</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-06</xbrli:startDate><xbrli:endDate>2025-01-06</xbrli:endDate></xbrli:period></xbrli:context></ix:resources></ix:header></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:1pt;padding-top:1pt;text-align:center;border-bottom:1px solid #000000;border-top:3.0pt solid #000000;margin:0pt;"><span style="font-size:1pt;font-weight:bold;visibility:hidden;">&#8203;</span></p><a id="_effcee29_ff14_4dd5_b906_b4fa6e7a9b0e"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:3pt 0pt 0pt 0pt;"><b style="font-size:16pt;font-weight:bold;">UNITED STATES</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-size:16pt;font-weight:bold;">SECURITIES AND EXCHANGE COMMISSION</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Washington, D.C. 20549</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:16pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">FORM </b><ix:nonNumeric contextRef="Duration_1_6_2025_To_1_6_2025_rbdgIz0CSUSvSHbyAAhdRA" name="dei:DocumentType" id="Narr_Dh87k9XnCkia8ucUDi0Z6w"><b style="font-weight:bold;">8-K</b></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">CURRENT REPORT</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Pursuant to Section&#160;13 or 15(d) of</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">the Securities Exchange Act of 1934</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-size:9pt;font-weight:bold;">Date of report (Date of earliest event reported): </b><ix:nonNumeric contextRef="Duration_1_6_2025_To_1_6_2025_rbdgIz0CSUSvSHbyAAhdRA" format="ixt:date-monthname-day-year-en" name="dei:DocumentPeriodEndDate" id="Narr_fBpGrwx4QU-gkh7w6508qg"><b style="font-size:9pt;font-weight:bold;">January 6, 2025</b></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:16pt;text-align:center;border-bottom:1.0pt solid #000000;margin:0pt;"><ix:nonNumeric contextRef="Duration_1_6_2025_To_1_6_2025_rbdgIz0CSUSvSHbyAAhdRA" name="dei:EntityRegistrantName" id="Narr_Prju1mpuLEudtQNk1tUCRg"><b style="font-weight:bold;">Y-MABS THERAPEUTICS, INC.</b></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">(Exact name of registrant as specified in its charter)</b></p><a id="_497c3b9f_9bdf_4a81_adf1_38678645cf23"></a><a id="Tc_ucmGIF5u9Uq9Eq_xuMFATw_2_0"></a><a id="Tc_UEHzsNW1uku3Np-RmdvRGg_2_2"></a><a id="Tc_QriTRCTINUGb1JAB2GG_sA_2_4"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:32%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td style="vertical-align:bottom;width:1.99%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:top;width:32%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td style="vertical-align:bottom;width:1.99%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:top;width:32%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td></tr><tr><td style="vertical-align:top;width:32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_1_6_2025_To_1_6_2025_rbdgIz0CSUSvSHbyAAhdRA" format="ixt-sec:stateprovnameen" name="dei:EntityIncorporationStateCountryCode" id="Tc_CclIF2HcV0KnM0MBxU1l4A_1_0"><b style="font-size:9pt;font-weight:bold;">Delaware</b></ix:nonNumeric></p></td><td style="vertical-align:bottom;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:top;width:32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_1_6_2025_To_1_6_2025_rbdgIz0CSUSvSHbyAAhdRA" name="dei:EntityFileNumber" id="Tc_ceqIQDdrZESNV5EEZFHe7g_1_2"><b style="font-size:9pt;font-weight:bold;">001-38650</b></ix:nonNumeric></p></td><td style="vertical-align:bottom;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:top;width:32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_1_6_2025_To_1_6_2025_rbdgIz0CSUSvSHbyAAhdRA" name="dei:EntityTaxIdentificationNumber" id="Tc_-6ADOGIL10GDtzLXJ5RUTQ_1_4"><b style="font-size:9pt;font-weight:bold;">47-4619612</b></ix:nonNumeric></p></td></tr><tr><td style="vertical-align:top;width:32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(State or other jurisdiction of</b><b style="font-weight:bold;"><br/></b><b style="font-weight:bold;">incorporation or organization)</b></p></td><td style="vertical-align:bottom;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(Commission</b><b style="font-weight:bold;"><br/></b><b style="font-weight:bold;">File Number)</b></p></td><td style="vertical-align:bottom;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(I.R.S. Employer</b><b style="font-weight:bold;"><br/></b><b style="font-weight:bold;">Identification No.)</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_1_6_2025_To_1_6_2025_rbdgIz0CSUSvSHbyAAhdRA" name="dei:EntityAddressAddressLine1" id="Narr_MK-vCMsKl0CJUl4w4dU3BA"><b style="font-size:9pt;font-weight:bold;">230 Park Avenue</b></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_1_6_2025_To_1_6_2025_rbdgIz0CSUSvSHbyAAhdRA" name="dei:EntityAddressAddressLine2" id="Narr_yHVVjB7zY0uw_fLsfWyx9g"><b style="font-size:9pt;font-weight:bold;">Suite 3350</b></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_1_6_2025_To_1_6_2025_rbdgIz0CSUSvSHbyAAhdRA" name="dei:EntityAddressCityOrTown" id="Narr_va6VGrLWUEOXX7nrgfF7pA"><b style="font-size:9pt;font-weight:bold;">New York</b></ix:nonNumeric><b style="font-size:9pt;font-weight:bold;">, </b><ix:nonNumeric contextRef="Duration_1_6_2025_To_1_6_2025_rbdgIz0CSUSvSHbyAAhdRA" format="ixt-sec:stateprovnameen" name="dei:EntityAddressStateOrProvince" id="Narr_A2aFAujcwEa_osyZgVlcCA"><b style="font-size:9pt;font-weight:bold;">New York</b></ix:nonNumeric><b style="font-size:9pt;font-weight:bold;"> </b><ix:nonNumeric contextRef="Duration_1_6_2025_To_1_6_2025_rbdgIz0CSUSvSHbyAAhdRA" name="dei:EntityAddressPostalZipCode" id="Narr__JanlHeFKUmf6_ikV7tomA"><b style="font-size:9pt;font-weight:bold;">10169</b></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(Address of principal executive offices) (Zip Code)</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-size:9pt;font-weight:bold;">(</b><ix:nonNumeric contextRef="Duration_1_6_2025_To_1_6_2025_rbdgIz0CSUSvSHbyAAhdRA" name="dei:CityAreaCode" id="Narr_zAxq0XqCMkWMZMhgvDc5YA"><b style="font-size:9pt;font-weight:bold;">646</b></ix:nonNumeric><b style="font-size:9pt;font-weight:bold;">) </b><ix:nonNumeric contextRef="Duration_1_6_2025_To_1_6_2025_rbdgIz0CSUSvSHbyAAhdRA" name="dei:LocalPhoneNumber" id="Narr_MYiWytRkhUKmB1cm0bT_2w"><b style="font-size:9pt;font-weight:bold;">885-8505</b></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(Registrant&#8217;s telephone number, include area code)</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">N/A</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(Former Name or Former Address, if Changed Since Last Report)</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:19.4pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;"><ix:nonNumeric contextRef="Duration_1_6_2025_To_1_6_2025_rbdgIz0CSUSvSHbyAAhdRA" format="ixt-sec:boolballotbox" name="dei:WrittenCommunications" id="Narr_nC0_AMdcnUi7JaBtBFnKMA"><span style="font-family:'Segoe UI Symbol';font-size:9pt;">&#9744;</span></ix:nonNumeric></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;"><span style="font-size:9pt;">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:19.4pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;"><ix:nonNumeric contextRef="Duration_1_6_2025_To_1_6_2025_rbdgIz0CSUSvSHbyAAhdRA" format="ixt-sec:boolballotbox" name="dei:SolicitingMaterial" id="Narr_-ajk1hFW3UacR79c_0lXqw"><span style="font-family:'Segoe UI Symbol';font-size:9pt;">&#9744;</span></ix:nonNumeric></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;"><span style="font-size:9pt;">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:19.4pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;"><ix:nonNumeric contextRef="Duration_1_6_2025_To_1_6_2025_rbdgIz0CSUSvSHbyAAhdRA" format="ixt-sec:boolballotbox" name="dei:PreCommencementTenderOffer" id="Narr_5o2RTj3Md02-JnS4d7r54w"><span style="font-family:'Segoe UI Symbol';font-size:9pt;">&#9744;</span></ix:nonNumeric></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;"><span style="font-size:9pt;">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:19.4pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;"><ix:nonNumeric contextRef="Duration_1_6_2025_To_1_6_2025_rbdgIz0CSUSvSHbyAAhdRA" format="ixt-sec:boolballotbox" name="dei:PreCommencementIssuerTenderOffer" id="Narr_HeXVVG7NwUiM4lEbsABUPg"><span style="font-family:'Segoe UI Symbol';font-size:9pt;">&#9744;</span></ix:nonNumeric></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;"><span style="font-size:9pt;">Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">Securities registered pursuant to Section 12(b) of the Act:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_0786e809_1893_41af_b9b7_02914857d87e"></a><a id="Tc_H1ivbgwnGkGt_pC7c44-hA_1_0"></a><a id="Tc_9mohvfxB_U2wJCyLXi8HgA_1_2"></a><a id="Tc_EtMedgI5PkOLtj3583RFOQ_1_4"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:32%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;width:1.99%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;width:32%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;width:1.99%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;width:32%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td></tr><tr><td style="vertical-align:bottom;width:32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Title&#160;of&#160;each&#160;class:</b></p></td><td style="vertical-align:bottom;width:1.99%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;width:32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Trading Symbol</b></p></td><td style="vertical-align:bottom;width:1.99%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;width:32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Name&#160;of&#160;each&#160;exchange&#160;on&#160;which registered:</b></p></td></tr><tr><td style="vertical-align:top;width:32%;border-top:1px solid #000000;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_1_6_2025_To_1_6_2025_rbdgIz0CSUSvSHbyAAhdRA" name="dei:Security12bTitle" id="Tc_H3fWjJjYrkCYiDn0_wl0hQ_2_0"><span style="font-size:9pt;">Common Stock, $0.0001 par value</span></ix:nonNumeric></p></td><td style="vertical-align:top;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:32%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_1_6_2025_To_1_6_2025_rbdgIz0CSUSvSHbyAAhdRA" name="dei:TradingSymbol" id="Tc_PobH5ysC0kqpxeyFz0hOAw_2_2"><span style="font-size:9pt;">YMAB</span></ix:nonNumeric></p></td><td style="vertical-align:bottom;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:32%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_1_6_2025_To_1_6_2025_rbdgIz0CSUSvSHbyAAhdRA" format="ixt-sec:exchnameen" name="dei:SecurityExchangeName" id="Tc_lSuC_Ton3UewnFYvuOLUeQ_2_4"><span style="font-size:9pt;">NASDAQ Global Select Market</span></ix:nonNumeric></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&#167;230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (&#167;240.12b-2 of this chapter).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;">Emerging growth company&#160; </span><ix:nonNumeric contextRef="Duration_1_6_2025_To_1_6_2025_rbdgIz0CSUSvSHbyAAhdRA" format="ixt-sec:boolballotbox" name="dei:EntityEmergingGrowthCompany" id="Narr_lGJ8q8VFXkCSjbbyrZqvmw"><span style="font-family:'Segoe UI Symbol';font-size:9pt;">&#9744;</span></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 3pt 0pt;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.&#160;&#160;<span style="font-family:'Segoe UI Symbol';">&#9744;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:1pt;padding-top:1pt;text-align:center;border-bottom:3.0pt solid #000000;border-top:1px solid #000000;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p><p style="display:none;font-family:'Times New Roman','Times','serif';line-height:0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><a id="_24a23bbf_6610_465a_8557_9848b4da03c1"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><b style="font-weight:bold;">ITEM 2.02. RESULTS OF OPERATIONS AND FINANCIAL CONDITION.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">On January 9, 2025, Y-mAbs Therapeutics, Inc. (the &#8220;Company&#8221;) announced a business realignment plan, as described in greater detail in Items 2.05 and 7.01 below, designed to optimize the Company&#8217;s operations by aligning dedicated internal resources to two business units, with the goal of increasing operational flexibility and speed, and accelerating clinical development programs within the Company&#8217;s radiopharmaceutical platform. In addition, the Company reported preliminary estimated unaudited total net revenue of approximately $88 million for the year ended December 31, 2024, within the previously announced estimated guidance range of between approximately $87 million and $95 million. In addition, the Company announced that it expects its operating expenses for the year ended December 31, 2024, including the impact of any business realignment charges recorded in the 2024 fiscal year, to be within the previously announced estimated guidance range of between $115 million and $120 million. The Company also reported preliminary estimated unaudited cash and cash equivalents as of December 31, 2024 of approximately $67 million with a total annual cash investment of approximately $11 million for the 2024 fiscal year, which is below the previously announced estimated guidance range of between $15 million to $20 million. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">The full text of the Company&#8217;s press release issued in connection with the announcement is furnished herewith as Exhibit 99.1 and is incorporated herein by reference.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">The preliminary 2024 financial results and expectations set forth above are unaudited and based on management&#8217;s initial review of the Company&#8217;s results as of and for the year ended December 31, 2024, and are subject to revision based upon the Company&#8217;s year-end closing procedures and the completion of the audit by the Company&#8217;s external auditors of the Company&#8217;s December 31, 2024 financial statements. Actual results may differ materially from these preliminary results as a result of the completion of year-end closing procedures, final adjustments, and other developments arising between now and the time that the Company&#8217;s financial results are finalized. In addition, these preliminary results are not a comprehensive statement of the Company&#8217;s financial results as of and for the year ended December 31, 2024, should not be viewed as a substitute for complete financial statements prepared in accordance with U.S. generally accepted accounting principles, and are not necessarily indicative of the Company&#8217;s results for any future period.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">The information in this Item 2.02 of this Current Report on Form 8-K is being furnished to the Securities and Exchange Commission and shall not be deemed &#8220;filed&#8221; for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;), or otherwise subject to liability under that section, nor shall it be deemed incorporated by reference in any filing under the Exchange Act or the Securities Act of 1933, as amended (the &#8220;Securities Act&#8221;), except as expressly set forth by specific reference in such a filing.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_919c6534_53cf_419a_8f5b_5902ce6b26ea"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">ITEM 2.05. COSTS ASSOCIATED WITH EXIT OR DISPOSAL ACTIVITIES.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="white-space:pre-wrap;">On January 6, 2025, the Company&#8217;s Board of Directors approved a business realignment plan designed to optimize the Company&#8217;s operations by aligning dedicated internal resources to two business units, with the goal of increasing operational flexibility and speed, and accelerating clinical development within its radiopharmaceutical platform.  Pursuant to the plan, the Company will have two business units, one that is focused on expanding market access to DANYELZA and progressing the clinical and commercial development of naxitamab in other indications and for potential label expansion, and another that is focused on progressing the radiopharmaceutical platform, including Self-Assembly Disassembly Pretargeted (&#8220;SADA PRIT&#8221;) technology platform and the Company&#8217;s early-stage pipeline, with a shared general administrative function. </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="white-space:pre-wrap;">In connection with this business realignment, the Company expects a reduction in its current workforce by up to approximately 13%, depending on whether a number of the impacted employees accept newly created positions.  This percentage substantially reflects the following: first, a small adjustment of the DANYELZA commercial team to focus the team on potential growth opportunities within the GD2 market, and second the relocation of some SADA development functions to the United States from Denmark, with such reduction anticipated to be completed by the end of the second quarter of 2025. Affected employees will be offered separation benefits in exchange for their execution of a severance agreement and general release.  The separation benefits include but are not limited to severance payments, payout of 2025 statutory bonuses, outplacement services, along with temporary healthcare coverage assistance.  </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">As a result of the reduction in workforce and realignment plan, the Company expects to incur restructuring expenses of up to approximately $2.6 million, consisting predominantly of cash-related notice and severance payments of up to </p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="white-space:pre-wrap;">approximately $2.1 million and acceleration of stock-based compensation of up to approximately $0.5 million. The Company anticipates that the restructuring expenses will impact its results of operations during the fourth quarter of 2024 and first quarter of 2025 and that the cash payments will occur through the first half of 2026.  The charges that the Company expects to incur are subject to a number of assumptions, and actual expenses may differ materially from the estimates disclosed above.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_f043ea55_ef51_4205_b238_0d4185523035"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">ITEM 5.02. DEPARTURE OF DIRECTORS OR CERTAIN OFFICERS; ELECTION OF DIRECTORS; APPOINTMENT OF CERTAIN OFFICERS; COMPENSATORY ARRANGEMENTS OF CERTAIN OFFICERS.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">In connection with this business realignment described in above, Susan Smith, the Company&#8217;s Senior Vice President and Chief Commercial Officer, will be departing from the Company on April 9, 2025.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_7956547e_4758_44eb_8aed_479131549426"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">ITEM 7.01 REGULATION FD DISCLOSURE.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">In connection with the business realignment described above, effective January 7, 2025, the Board of Directors of the Company appointed Doug Gentilcore to serve as the Company&#8217;s SVP, Danyelza Business Unit Head. The Company has also appointed Natalie Tucker, previously the Company&#8217;s Vice President of Business Development and Chief of Staff, to be promoted to the role of SVP, Radiopharmaceutical Business Head.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">On January 10, 2025, the Company issued a press release announcing Strategic Business Updates and 2025 Priorities, including the business realignment discussed above and the anticipated timing of certain trial data regulatory matters. The full text of the Company&#8217;s press release is furnished herewith as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">The information in this Item 7.01 of this Current Report on Form 8-K is being furnished to the Securities and Exchange Commission and shall not be deemed &#8220;filed&#8221; for purposes of Section 18 of the Exchange Act or otherwise subject to liability under that section, nor shall it be deemed incorporated by reference in any filing under the Exchange Act or the Securities Act of 1933, as amended, except as expressly set forth by specific reference in such a filing.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><i style="font-style:italic;">Cautionary Statement Regarding Forward-Looking Statements</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">Statements in this Current Report on Form 8-K about future expectations, plans and prospects, as well as any other statements regarding matters that are not historical facts, may constitute &#8220;forward-looking statements&#8221; within the meaning of The Private Securities Litigation Reform Act of 1995. Such statements include, but are not limited to, statements about: our business model, expectations with respect to estimated charges and expenses in connection with the business realignment plan, including the amounts and timing thereof, preliminary estimated financial results and expectations for the year ended December 31, 2024, including estimated operating expenses, cash and cash equivalents and net revenue; the realignment plan,/ including the reduction in workforce and operations and resources, and the expected impacts, anticipated expenses and benefits thereof, including operational flexibility and speed, and acceleration of clinical development within the radiopharmaceutical platform expectations with respect to trial data and regulatory matters; implied and express statements regarding the future of the Company&#8217;s business; the Company&#8217;s strategies, development, regulatory, commercialization and product distribution plans; and other statements that are not historical facts. Words such as &#8220;anticipate,&#8221; &#8220;believe,&#8221; &#8220;contemplate,&#8221; &#8220;continue,&#8221; &#8220;could,&#8221; &#8220;estimate,&#8221; &#8220;expect,&#8221; &#8220;goal,&#8221; &#8220;guidance,&#8221; &#8220;hope,&#8221; &#8220;intend,&#8221; &#8220;may,&#8221; &#8220;might,&#8221; &#8220;plan,&#8221; &#8220;potential,&#8221; &#8220;predict,&#8221; &#8220;project,&#8221; &#8220;should,&#8221; &#8220;target,&#8221; &#8220;will,&#8221; &#8220;would&#8221; and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Our product candidates and related technologies are novel approaches to cancer treatment that present significant challenges. Actual results may differ materially from those indicated by such forward-looking statements as a result of various factors, including but not limited to: risks associated with our financial condition and need for additional capital; the risk that our reported results may differ materially from our preliminary estimated operating expense, cash and cash equivalent and DANYELZA net product revenue results as a result of the completion of year-end closing procedures, final adjustments, and other developments arising between now and the time that our financial results are finalized; the risks that actual results of the business realignment plan will not be as expected, including the impact on employees and other parties; risks associated with our development work; cost and success of our product development activities and clinical trials; the risks of delay in the timing of our regulatory submissions or failure to receive approval of our drug candidates; the risks related to commercializing any approved pharmaceutical product including the rate and degree of market acceptance of our product candidates; development of </p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">our sales and marketing capabilities and risks associated with failure to obtain sufficient reimbursement for our products; the risks related to our dependence on third parties including for conduct of clinical testing and product manufacture; risks related to our ability to enter into partnerships; the risks related to government regulation; risks related to market approval, risks associated with protection of our intellectual property rights; risks related to employee matters and managing growth; risks related to our common stock; risks associated with ongoing geopolitical conflicts; and other risks and uncertainties affecting the Company including those described in the &#8220;Risk Factors&#8221; section included in our Annual Report on Form 10-K for the year ended December 31, 2023, our Quarterly Reports on Form 10-Q for the quarters ended March 31, June 30, and September 30, 2024, and in our other SEC filings. Any forward-looking statements contained in this Current Report on Form 8-K speak only as of the date hereof, and the Company undertakes no obligation to update any forward-looking statement, whether as a result of new information, future events or otherwise.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_a78a8af6_12f1_48ad_b851_21625251808b"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">ITEM 9.01. FINANCIAL STATEMENTS AND EXHIBITS.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">(d) Exhibits</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:10.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:87.68%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:10.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Exhibit No.</b></p></td><td style="vertical-align:bottom;width:2.06%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:87.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Description</b></p></td></tr><tr><td style="vertical-align:middle;width:10.25%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td colspan="2" style="vertical-align:middle;width:89.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:10.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">99.1</p></td><td style="vertical-align:bottom;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:87.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="ymab-20250106xex99d1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Press Release, dated January 10, 2025, issued by Y-mAbs Therapeutics, Inc.</span></a></p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:10.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:87.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:10.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">104</p></td><td style="vertical-align:bottom;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:87.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Interactive Data File (embedded within the Inline XBRL document).</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_4b7181ac_dc88_4578_af63_4ba4c3f579d7"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">SIGNATURES</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:50.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:top;width:3.69%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:46.21%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:50.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:top;width:49.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Y-MABS THERAPEUTICS, INC.</p></td></tr><tr><td style="vertical-align:bottom;width:50.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:3.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:46.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:50.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Date: January 10, 2025</p></td><td style="vertical-align:top;width:3.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:46.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:50.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:3.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">By:</p></td><td style="vertical-align:bottom;width:46.21%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">/s/ Michael Rossi</p></td></tr><tr><td style="vertical-align:bottom;width:50.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:3.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:46.21%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Michael Rossi</p></td></tr><tr><td style="vertical-align:bottom;width:50.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:3.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:46.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">President and Chief Executive Officer</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;margin-left:10.35%;margin-right:10.35%;margin-top:30pt;page-break-after:avoid;width:79.3%;border:0;"></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>ymab-20250106xex99d1.htm
<DESCRIPTION>EX-99.1
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  10.6.128.0--><!--Created on: 1/10/2025 12:19:55 PM (UTC)--><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">Exhibit 99.1</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 10pt 0pt;"><img src="ymab-20250106xex99d1001.jpg" alt="Graphic" style="display:inline-block;height:32.24pt;left:0%;padding-bottom:0pt;position:relative;top:0pt;width:214.47pt;"></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-size:16pt;font-weight:bold;">Y-mAbs Provides Strategic Business Update and 2025 Priorities</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Company establishes two business units with goal of accelerating clinical development of its Radiopharmaceuticals Platform and optimizing the commercial potential of DANYELZA</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Preliminary Part A data from GD2-SADA Phase 1 trial demonstrates tolerability and validity of SADA PRIT platform pre-targeting approach; Company expects to present Part A data in the second quarter of 2025</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Company reports preliminary estimated unaudited Total Net Revenue of approximately $88 million for the year ended December 31, 2024, within Full Year 2024 top line guidance range</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Company reports preliminary estimated unaudited cash, cash equivalents and marketable securities of approximately $67 million as of December 31, 2024, anticipated to support operations into 2027</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Company presenting at 43</i><sup style="font-size:7.5pt;font-style:italic;vertical-align:top;">rd</sup><i style="font-style:italic;"> Annual J.P. Morgan Healthcare Conference on Wednesday, January 15, 2024 at 5:15 p.m. PT</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">New York, NY, January 10, 2025 &#8211; Y-mAbs Therapeutics, Inc. (the &#8220;Company&#8221; or &#8220;Y-mAbs&#8221;) (Nasdaq: YMAB), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel radioimmunotherapy and antibody-based therapeutic products for the treatment of cancer, today announced strategic business updates and 2025 priorities in the Company&#8217;s mission to improve and extend people&#8217;s lives.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Business Update</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">Y-mAbs is internally realigning operations with the establishment of two business units: Radiopharmaceuticals and DANYELZA.</p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Radiopharmaceuticals</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:54pt;"></td><td style="font-family:'Courier New';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">o</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Novel Self-Assembly DisAssembly Pre-targeted Radioimmunotherapy (</font><font style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">&#8220;</font><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">SADA PRIT</font><font style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">&#8221;</font><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">) platform designed to improve upon traditional radioimmunotherapy by delivering high therapeutic dose while minimizing off-target exposure, increase physician participation and decrease manufacturing and infrastructure costs.</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:54pt;"></td><td style="font-family:'Courier New';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">o</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">SADA PRIT technology utilizes a pre-targeted payload delivery method where antibody constructs assemble in tetramers and bind to the tumor target.</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:54pt;"></td><td style="font-family:'Courier New';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">o</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Platform can deliver a variety of payloads and could potentially be developed against multiple tumor targets, as well as for radiopharmaceutical purposes.</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:54pt;"></td><td style="font-family:'Courier New';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">o</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Y-mAbs is currently evaluating its SADA PRIT technology in two clinical trials in the U.S.</font></td></tr></table><div style="margin-top:10pt;"></div><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">DANYELZA</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:54pt;"></td><td style="font-family:'Courier New';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">o</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">DANYELZA is a GD2 antibody and the only FDA-approved treatment for the treatment of patients one-year of age and older with high-risk relapsed/refractory neuroblastoma in the bone and bone marrow.</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:54pt;"></td><td style="font-family:'Courier New';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">o</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Initially commercially launched in 2021, DANYELZA is commercialized across both U.S. and international markets.</font></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="display:none;font-family:'Times New Roman','Times','serif';line-height:0pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:0pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:10.35%;margin-right:10.35%;margin-top:30pt;page-break-after:always;width:79.3%;border-width:0;"><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 8pt 0pt;"><img src="ymab-20250106xex99d1001.jpg" alt="Graphic" style="display:inline-block;height:32.24pt;left:0%;padding-bottom:0pt;position:relative;top:0pt;width:214.47pt;"></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">The business realignment is designed to support the optimization of internal resources and provide flexibility and agility to advance the Company&#8217;s novel SADA PRIT platform programs through clinical development while simultaneously driving commercial growth of DANYELZA.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">&#8220;Our mission at Y-mAbs has been clear from day one: bring important new cancer therapies to patients as quickly as possible. Since the successful commercial launch of DANYELZA, we are proud to have positively impacted the lives of children with high-risk relapsed/refractory neuroblastoma, giving the hope of a better future to families around the world,&#8221; said Michael Rossi, President and Chief Executive Officer. &#8220;As we look ahead towards the potential of our novel Radiopharmaceutical platform and high value therapeutic areas, as well as the potential of DANYELZA, we believe now is the right time to focus our efforts into two business units. By doing so, we expect to expand our radiopharmaceutical capabilities, accelerate clinical execution, further improve capital efficiencies, and better align strategic priorities.&#8221;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">With these updates to our business strategy, the Company anticipates a reduction in its current workforce of up to approximately 13%, depending on whether a portion of impacted employees accept newly created positions. The Company also intends to move some roles from Denmark to the U.S. to more efficiently coordinate the advancement of its radiopharmaceutical platform, and implement a small adjustment to the DANYELZA commercial team to focus the team on potential growth opportunities within the anti-GD2 market.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">Recent Pipeline Advancement</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">GD2-SADA (Trial 1001):</b> Y-mAbs has dosed 21 patients at six sites to date in Part A of the GD2-SADA Phase 1 trial in adults with solid tumors. Tumor types include small cell lung cancer (SCLC), malignant melanoma, sarcomas and adult neuroblastoma. Preliminary data from the Part A GD2-SADA Phase 1 trial has demonstrated this novel pre-targeting approach to be well-tolerated with no dose-limiting toxicities (DLTs) and no treatment-related adverse events (AEs) reported. Part A remains ongoing as the Company aggregates final data on patients in open cohorts and continues to study further patients incorporating various elements to further optimize the platform aiming to maximize tumor uptake and retention. The Company expects to share data from Part A in the second quarter of 2025.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">&#8220;The preliminary data from Part A of our GD2-SADA Phase 1 trial demonstrates the viability of the pre-targeted approach of the platform. We continue to gather learnings from the 21 patients dosed to date, which we anticipate will allow us to improve tumor uptake, determine the optimal therapeutic dose, and establish the ideal construct to further advance Trial 1001 in the clinic,&#8221; said Norman LaFrance, M.D., Chief Development Officer. &#8220;We believe in the significant potential of our SADA PRIT platform, and we are excited to be at the forefront of this next-generation, pre-targeted radiotherapy technology.&#8221;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">CD38-SADA (Trial 1201):</b> To date, six sites have been selected, and three sites have been activated. The Company expects to dose the first non-Hodgkin Lymphoma (NHL) patient in Study 1201 in the first quarter of 2025. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">Unaudited Preliminary FY2024 Results</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">Y-mAbs reported preliminary estimated unaudited full year 2024 total net revenue of approximately $88 million, within the Company&#8217;s previously announced guidance range of between $87 million and $95 million, and preliminary estimated unaudited cash, cash equivalents and marketable securities as of December 31, 2024 of approximately $67 million, with preliminary estimated total cash investment for the full year 2024 of approximately $11 million, which is below the Company&#8217;s guidance range of between $15 million and $20 million.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">Anticipated 2025 Milestones</b></p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Part A data from GD2-SADA Phase 1 trial (Trial 1001) expected to be presented in the second quarter of 2025</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">GD2-SADA optimization data expected to be presented in the second quarter of 2025</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Expect to present updates with respect to reprioritized SADA PRIT pipeline, including new high-value target indications and timelines, in the second quarter of 2025</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Expect to dose first patient in CD38-SADA Phase 1 trial (Trial 1201) in the first quarter of 2025</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Potential for marketing approval for DANYELZA in new ex-US market in 2025</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Plan to provide full year 2025 guidance in conjunction with full year 2024 earnings report in the first quarter of 2025</font></td></tr></table></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:10.35%;margin-right:10.35%;margin-top:30pt;page-break-after:always;width:79.3%;border-width:0;"><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 8pt 0pt;"><img src="ymab-20250106xex99d1001.jpg" alt="Graphic" style="display:inline-block;height:32.24pt;left:0%;padding-bottom:0pt;position:relative;top:0pt;width:214.47pt;"></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">Upcoming Investor Presentation</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">The company previously announced that Mr. Rossi will present at the 43<sup style="font-size:7.5pt;vertical-align:top;">rd</sup> Annual J.P. Morgan Healthcare Conference in San Francisco, CA on Wednesday, January 15, 2025 at 5:15 p.m. PT. A live webcast will be available under the Events section of the Company&#8217;s investor relations website at ir.ymabs.com. The webcast will be archived and available for replay for 30 days after the event. &#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><b style="font-weight:bold;">About Y-mAbs </b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">Y-mAbs is a commercial-stage biopharmaceutical company focused on the development and commercialization of novel, radioimmunotherapy and antibody-based therapeutic cancer products. The Company&#8217;s technologies include its investigational Self-Assembly DisAssembly (&#8220;SADA&#8221;) Pretargeted Radioimmunotherapy Platform (&#8220;PRIT&#8221;) and bispecific antibodies generated using the Y-BiClone platform. The Company&#8217;s broad and advanced product pipeline includes the anti-GD2 therapy DANYELZA&#174; (naxitamab-gqgk), the first FDA-approved treatment for patients with relapsed or refractory high-risk neuroblastoma in the bone or bone marrow after a partial response, minor response, or stable disease to prior therapy.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><b style="font-weight:bold;">Forward-Looking Statements</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Statements in this press release about future expectations, plans and prospects, as well as any other statements regarding matters that are not historical facts, may constitute &#8220;forward-looking statements&#8221; within the meaning of The Private Securities Litigation Reform Act of 1995. Such statements include, but are not limited to, statements about: our business model, expectations with respect to estimated charges and expenses in connection with the business realignment plan, including the amounts and timing thereof, preliminary estimated financial results and expectations for the year ended December 31, 2024, including estimated operating expenses, cash and cash equivalents and net revenue; the realignment plan, including the reduction in workforce and operations and resources, and the expected impacts, anticipated expenses and benefits thereof, including operational flexibility and acceleration of clinical development within the radiopharmaceutical platform; implied and express statements regarding the future of the Company&#8217;s business; the Company&#8217;s strategies, development, regulatory, commercialization and product distribution plans; expectations with respect to the Company&#8217;s products and product candidates, including market access expansion of DANYELZA and the potential market opportunity related thereto and potential benefits thereof, and the potential of the SADA PRIT technology platform and product candidates based on such technology; expectations relating to key anticipated development milestones, including potential expansion of international commercialization efforts with respect to DANYELZA and the SADA PRIT technology, including anticipated collection and presentation of data, and the timing thereof; current and future clinical and pre-clinical studies and our research and development programs; expectations related to the timing of the initiation and completion of regulatory submissions; regulatory, marketing and reimbursement approvals; and other statements that are not historical facts. Words such as &#8220;anticipate,&#8221; &#8220;believe,&#8221; &#8220;contemplate,&#8221; &#8220;continue,&#8221; &#8220;could,&#8221; &#8220;estimate,&#8221; &#8220;expect,&#8221; &#8220;goal,&#8221; &#8220;guidance,&#8221; &#8220;hope,&#8221; &#8220;intend,&#8221; &#8220;may,&#8221; &#8220;might,&#8221; &#8220;plan,&#8221; &#8220;potential,&#8221; &#8220;predict,&#8221; &#8220;project,&#8221; &#8220;should,&#8221; &#8220;target,&#8221; &#8220;will,&#8221; &#8220;would&#8221; and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Our product candidates and related technologies are novel approaches to cancer treatment that present significant challenges. Actual results may differ materially from those indicated by such forward-looking statements as a result of various factors, including but not limited to: risks associated with our financial condition and need for additional capital; the risk that our reported results may differ materially from our preliminary estimated operating expense, cash and cash equivalent and DANYELZA net product revenue results as a result of the completion of year-end closing procedures, final adjustments, and other developments arising between now and the time that our financial results are finalized; the risks that actual results of the business realignment plan will not be as expected, including the impact on employees and other parties; risks associated with our development work; cost and success of our product development activities and clinical trials; the risks of delay in the timing of our regulatory submissions or failure to receive approval of our drug candidates; the risks related to commercializing any approved pharmaceutical product including the rate and degree of market acceptance of our product candidates; development of our sales and marketing capabilities and risks associated with failure to obtain sufficient reimbursement for our products; the risks related to our dependence on third parties including for conduct of clinical testing and product manufacture; risks related to our ability to enter into partnerships; the risks related to government regulation; risks related to market approval, risks associated with protection of our intellectual property rights; risks related to employee matters and managing growth; risks related to our common stock; risks associated with ongoing geopolitical conflicts; and other risks and uncertainties affecting the Company including those described in the &#8220;Risk Factors&#8221; section included in our Annual Report on Form 10-K for the year ended December 31, 2023, our Quarterly Reports on Form 10-Q for the quarters ended March 31, June 30, and September 30, 2024, and in our other SEC filings. Any forward-looking statements contained in this press release </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:10.35%;margin-right:10.35%;margin-top:30pt;page-break-after:always;width:79.3%;border-width:0;"><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 8pt 0pt;"><img src="ymab-20250106xex99d1001.jpg" alt="Graphic" style="display:inline-block;height:32.24pt;left:0%;padding-bottom:0pt;position:relative;top:0pt;width:214.47pt;"></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">speak only as of the date hereof, and the Company undertakes no obligation to update any forward-looking statement, whether as a result of new information, future events or otherwise.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">SADA&#174;, SADA PRIT&#174;, DANYELZA&#174; and Y-mAbs&#174; are registered trademarks of Y-mAbs Therapeutics, Inc.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><b style="font-weight:bold;">Investor Contact:</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Courtney Dugan</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">VP, Head of Investor Relations</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">cdu@ymabs.com</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:10.35%;margin-right:10.35%;margin-top:30pt;page-break-after:avoid;width:79.3%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>ymab-20250106xex99d1001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ymab-20250106xex99d1001.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1"  K 1X# 2(  A$! Q$!_\0
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M$\7?\FQ?L_?]AO5/_2I:^Y?VB?C$]Q9CX<^%XY;[7[\);W9A4_NU8 ^6OJS
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M?Q"T;'4X+1[))-QP(F9788^JCFE?PO82>*8O$+1L=3CLVL5DW';Y3.'(QZY
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G HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>4
<FILENAME>ymab-20250106.xsd
<DESCRIPTION>EX-101.SCH
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--XBRL document created with Toppan Merrill Bridge  10.9.0.3 -->
<!--Based on XBRL 2.1-->
<!--Created on: 1/10/2025 12:20:02 PM-->
<!--Modified on: 1/10/2025 12:20:02 PM-->
<xsd:schema targetNamespace="http://www.ymabs.com/20250106" attributeFormDefault="unqualified" elementFormDefault="qualified" xmlns:xsd="http://www.w3.org/2001/XMLSchema" xmlns:dei="http://xbrl.sec.gov/dei/2024" xmlns:srt-types="http://fasb.org/srt-types/2024" xmlns:deprecated="http://www.xbrl.org/2009/role/deprecated" xmlns:currency="http://xbrl.sec.gov/currency/2024" xmlns:dtr="http://www.xbrl.org/2009/dtr" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:cef="http://xbrl.sec.gov/cef/2024" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xl="http://www.xbrl.org/2003/XLink" xmlns:us-gaap="http://fasb.org/us-gaap/2024" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:sic="http://xbrl.sec.gov/sic/2024" xmlns:stpr="http://xbrl.sec.gov/stpr/2024" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:country="http://xbrl.sec.gov/country/2024" xmlns:enum2="http://xbrl.org/2020/extensible-enumerations-2.0" xmlns:us-roles="http://fasb.org/us-roles/2024" xmlns:naics="http://xbrl.sec.gov/naics/2024" xmlns:net="http://www.xbrl.org/2009/role/net" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:us-types="http://fasb.org/us-types/2024" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2022-03-31" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:negated="http://www.xbrl.org/2009/role/negated" xmlns:srt="http://fasb.org/srt/2024" xmlns:exch="http://xbrl.sec.gov/exch/2024" xmlns:srt-roles="http://fasb.org/srt-roles/2024" xmlns:attributeFormDefault="unqualified" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:snj="http://xbrl.sec.gov/snj/2024" xmlns:ymab="http://www.ymabs.com/20250106" xmlns:rxp="http://xbrl.sec.gov/rxp/2024q3" xmlns:us-gaap-ebp="http://fasb.org/us-gaap-ebp/2024" xmlns:cyd="http://xbrl.sec.gov/cyd/2024" xmlns:cyd-8k-sub="http://xbrl.sec.gov/cyd-8k-sub/2024" xmlns:cyd-af-sub="http://xbrl.sec.gov/cyd-af-sub/2024">
  <xsd:annotation>
    <xsd:appinfo>
      <link:roleType roleURI="http://www.ymabs.com/role/DocumentDocumentAndEntityInformation" id="DocumentDocumentAndEntityInformation">
        <link:definition>00090 - Document - Document and Entity Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:linkbaseRef xlink:type="simple" xlink:href="ymab-20250106_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
      <link:linkbaseRef xlink:type="simple" xlink:href="ymab-20250106_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
    </xsd:appinfo>
  </xsd:annotation>
  <xsd:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
  <xsd:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/dei/2024" schemaLocation="https://xbrl.sec.gov/dei/2024/dei-2024.xsd" />
</xsd:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>5
<FILENAME>ymab-20250106_lab.xml
<DESCRIPTION>EX-101.LAB
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--XBRL document created with Toppan Merrill Bridge  10.9.0.3 -->
<!--Based on XBRL 2.1-->
<!--Created on: 1/10/2025 12:20:02 PM-->
<!--Modified on: 1/10/2025 12:20:02 PM-->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xlink="http://www.w3.org/1999/xlink">
  <link:labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CoverAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document and Entity Information [Abstract]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentType" xlink:label="dei_DocumentType" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentType_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document Type</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodEndDate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document Period End Date</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityRegistrantName_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Registrant Name</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Incorporation, State or Country Code</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFileNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity File Number</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Tax Identification Number</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Address, Address Line One</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine2_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Address, Adress Line Two</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressStateOrProvince_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Address State Or Province</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCityOrTown_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Address, City or Town</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressPostalZipCode_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Address, Postal Zip Code</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CityAreaCode_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">City Area Code</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_LocalPhoneNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Local Phone Number</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_WrittenCommunications" xlink:label="dei_WrittenCommunications" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_WrittenCommunications" xlink:to="dei_WrittenCommunications_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_WrittenCommunications_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Written Communications</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SolicitingMaterial" xlink:label="dei_SolicitingMaterial" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SolicitingMaterial" xlink:to="dei_SolicitingMaterial_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SolicitingMaterial_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Soliciting Material</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementTenderOffer" xlink:label="dei_PreCommencementTenderOffer" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementTenderOffer" xlink:to="dei_PreCommencementTenderOffer_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementTenderOffer_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Pre-commencement Tender Offer</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="dei_PreCommencementIssuerTenderOffer" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementIssuerTenderOffer" xlink:to="dei_PreCommencementIssuerTenderOffer_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Pre-commencement Issuer Tender Offer</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12bTitle_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Title of 12(b) Security</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_TradingSymbol_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Trading Symbol</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityExchangeName_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Security Exchange Name</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Emerging Growth Company</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCentralIndexKey_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Central Index Key</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentFlag_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amendment Flag</label>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>6
<FILENAME>ymab-20250106_pre.xml
<DESCRIPTION>EX-101.PRE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--XBRL document created with Toppan Merrill Bridge  10.9.0.3 -->
<!--Based on XBRL 2.1-->
<!--Created on: 1/10/2025 12:20:02 PM-->
<!--Modified on: 1/10/2025 12:20:02 PM-->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xlink="http://www.w3.org/1999/xlink">
  <roleRef xlink:type="simple" xlink:href="ymab-20250106.xsd#DocumentDocumentAndEntityInformation" roleURI="http://www.ymabs.com/role/DocumentDocumentAndEntityInformation" xmlns="http://www.xbrl.org/2003/linkbase" />
  <presentationLink xlink:role="http://www.ymabs.com/role/DocumentDocumentAndEntityInformation" xlink:type="extended" xlink:title="00090 - Document - Document and Entity Information" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CoverAbstract" xlink:label="CoverAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentType" xlink:label="dei_DocumentType_638721084028723100" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_DocumentType_638721084028723100" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate_638721084028723100" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_DocumentPeriodEndDate_638721084028723100" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName_638721084028733142" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_EntityRegistrantName_638721084028733142" order="3" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode_638721084028733142" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_EntityIncorporationStateCountryCode_638721084028733142" order="4" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber_638721084028733142" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_EntityFileNumber_638721084028733142" order="5" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber_638721084028733142" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_EntityTaxIdentificationNumber_638721084028733142" order="6" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1_638721084028733142" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_EntityAddressAddressLine1_638721084028733142" order="7" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2_638721084028733142" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_EntityAddressAddressLine2_638721084028733142" order="8" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince_638721084028733142" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_EntityAddressStateOrProvince_638721084028733142" order="9" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown_638721084028733142" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_EntityAddressCityOrTown_638721084028733142" order="10" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode_638721084028733142" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_EntityAddressPostalZipCode_638721084028733142" order="11" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode_638721084028743096" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_CityAreaCode_638721084028743096" order="12" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber_638721084028743096" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_LocalPhoneNumber_638721084028743096" order="13" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_WrittenCommunications" xlink:label="dei_WrittenCommunications_638721084028743096" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_WrittenCommunications_638721084028743096" order="14" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SolicitingMaterial" xlink:label="dei_SolicitingMaterial_638721084028743096" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_SolicitingMaterial_638721084028743096" order="15" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementTenderOffer" xlink:label="dei_PreCommencementTenderOffer_638721084028743096" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_PreCommencementTenderOffer_638721084028743096" order="16" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="dei_PreCommencementIssuerTenderOffer_638721084028743096" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_PreCommencementIssuerTenderOffer_638721084028743096" order="17" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle_638721084028743096" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_Security12bTitle_638721084028743096" order="18" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol_638721084028753089" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_TradingSymbol_638721084028753089" order="19" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName_638721084028753089" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_SecurityExchangeName_638721084028753089" order="20" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany_638721084028753089" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_EntityEmergingGrowthCompany_638721084028753089" order="21" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey_638721084028753089" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_EntityCentralIndexKey_638721084028753089" order="22" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag_638721084028753089" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_AmendmentFlag_638721084028753089" order="23" use="optional" />
  </presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>8
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.4</span><table class="report" border="0" cellspacing="2" id="idm45973683404384">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Document and Entity Information<br></strong></div></th>
<th class="th"><div>Jan. 06, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Document and Entity Information [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Jan.  06,  2025<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">Y-MABS THERAPEUTICS, INC.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-38650<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">47-4619612<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">230 Park Avenue<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Adress Line Two</a></td>
<td class="text">Suite 3350<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address State Or Province</a></td>
<td class="text">NY<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">New York<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">10169<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">646<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">885-8505<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre-commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre-commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, $0.0001 par value<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">YMAB<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001722964<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14a<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>9
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M=]W3CHG&K=!X#;[Q3X?#KHG&J]!TZVDF)_VN:Z3I%FA"1N/K>A(5M>5 TR
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M!Z.:60F]A%9JGZJ'-#ZH'C(*!?&Y'C[E>G@*-Y;&O%"N@GL!_]':-\*K^(+
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MU4#E/]O4#6CV#30<D05>,9FV-J/D3@H\W/[O#;#"Q([A[8N_ 5!+ P04
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MT&P4W(U^PY@J@_?.,OA)PM3:1.D74- ;8QPI%?4IQ04;RZSR=P^WYP/:&(:
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MP %#TG1X#SY['R73>RHY_U=3_ 102P,$%     @ >$LJ6I>*NQS     $P(
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MB^$_7G\!4$L! A0#%     @ >$LJ6@=!36*!    L0   !
M ( !     &1O8U!R;W!S+V%P<"YX;6Q02P$"% ,4    " !X2RI:&ZM,<^\
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M<W1Y;&5S+GAM;%!+ 0(4 Q0    ( 'A+*EJ7BKL<P    !,"   +
M      "  8P/  !?<F5L<R\N<F5L<U!+ 0(4 Q0    ( 'A+*EH<.&7J/P$
M #P"   /              "  740  !X;"]W;W)K8F]O:RYX;6Q02P$"% ,4
M    " !X2RI:)!Z;HJT   #X 0  &@              @ 'A$0  >&PO7W)E
M;',O=V]R:V)O;VLN>&UL+G)E;'-02P$"% ,4    " !X2RI:99!YDAD!  #/
M P  $P              @ '&$@  6T-O;G1E;G1?5'EP97-=+GAM;%!+!08
1    "0 ) #X"   0%      !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>10
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
.report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

.report table.authRefData a {
	display: block;
	font-weight: bold;
}

.report table.authRefData p {
	margin-top: 0px;
}

.report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

.report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

.report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

.report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
.pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
.report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

.report hr {
	border: 1px solid #acf;
}

/* Top labels */
.report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

.report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

.report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

.report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

.report td.pl div.a {
	width: 200px;
}

.report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
.report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
.report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
.report .re, .report .reu {
	background-color: #def;
}

.report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
.report .ro, .report .rou {
	background-color: white;
}

.report .rou td {
	border-bottom: 1px solid black;
}

.report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
.report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
.report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

.report .nump {
	padding-left: 2em;
}

.report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
.report .text {
	text-align: left;
	white-space: normal;
}

.report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

.report .text .more {
	display: none;
}

.report .text .note {
	font-style: italic;
	font-weight: bold;
}

.report .text .small {
	width: 10em;
}

.report sup {
	font-style: italic;
}

.report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.24.4</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>23</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>0</UnitCount>
  <MyReports>
    <Report instance="ymab-20250106x8k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>00090 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ymabs.com/role/DocumentDocumentAndEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File>ymab-20250106.xsd</File>
    <File>ymab-20250106_lab.xml</File>
    <File>ymab-20250106_pre.xml</File>
    <File doctype="8-K" isOnlyDei="true" original="ymab-20250106x8k.htm">ymab-20250106x8k.htm</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="23">http://xbrl.sec.gov/dei/2024</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>15
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "ymab-20250106x8k.htm": {
   "nsprefix": "ymab",
   "nsuri": "http://www.ymabs.com/20250106",
   "dts": {
    "schema": {
     "local": [
      "ymab-20250106.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd",
      "https://xbrl.sec.gov/dei/2024/dei-2024.xsd"
     ]
    },
    "labelLink": {
     "local": [
      "ymab-20250106_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "ymab-20250106_pre.xml"
     ]
    },
    "inline": {
     "local": [
      "ymab-20250106x8k.htm"
     ]
    }
   },
   "keyStandard": 23,
   "keyCustom": 0,
   "axisStandard": 0,
   "axisCustom": 0,
   "memberStandard": 0,
   "memberCustom": 0,
   "hidden": {
    "total": 2,
    "http://xbrl.sec.gov/dei/2024": 2
   },
   "contextCount": 1,
   "entityCount": 1,
   "segmentCount": 0,
   "elementCount": 24,
   "unitCount": 0,
   "baseTaxonomies": {
    "http://xbrl.sec.gov/dei/2024": 23
   },
   "report": {
    "R1": {
     "role": "http://www.ymabs.com/role/DocumentDocumentAndEntityInformation",
     "longName": "00090 - Document - Document and Entity Information",
     "shortName": "Document and Entity Information",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "Duration_1_6_2025_To_1_6_2025_rbdgIz0CSUSvSHbyAAhdRA",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ymab-20250106x8k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_6_2025_To_1_6_2025_rbdgIz0CSUSvSHbyAAhdRA",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ymab-20250106x8k.htm",
      "first": true,
      "unique": true
     }
    }
   },
   "tag": {
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://www.ymabs.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CityAreaCode",
     "presentation": [
      "http://www.ymabs.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Document and Entity Information [Abstract]",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://www.ymabs.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentType",
     "presentation": [
      "http://www.ymabs.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://www.ymabs.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine2": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressAddressLine2",
     "presentation": [
      "http://www.ymabs.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Adress Line Two",
        "documentation": "Address Line 2 such as Street or Suite number"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://www.ymabs.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://www.ymabs.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://www.ymabs.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address State Or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://www.ymabs.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://www.ymabs.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://www.ymabs.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://www.ymabs.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Incorporation, State or Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://www.ymabs.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://www.ymabs.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://www.ymabs.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "PreCommencementIssuerTenderOffer",
     "presentation": [
      "http://www.ymabs.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-commencement Issuer Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "dei_PreCommencementTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "PreCommencementTenderOffer",
     "presentation": [
      "http://www.ymabs.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-commencement Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "Security12bTitle",
     "presentation": [
      "http://www.ymabs.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of 12(b) Security",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r0"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://www.ymabs.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_SolicitingMaterial": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "SolicitingMaterial",
     "presentation": [
      "http://www.ymabs.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Soliciting Material",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "TradingSymbol",
     "presentation": [
      "http://www.ymabs.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "dei_WrittenCommunications": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "WrittenCommunications",
     "presentation": [
      "http://www.ymabs.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Written Communications",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r1": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r2": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r3": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r4": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14a",
   "Subsection": "12"
  },
  "r5": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r6": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "425"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>16
<FILENAME>0001558370-25-000105-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001558370-25-000105-xbrl.zip
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M+G>%HFT-Z UHC$/,,9D\B6L8A@-=SUJ1Q="9FU+$'2HLQ:TD:%76MI:@/&L
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M=*M3+5%:6"7+G$UE"<="94LO'ZC&K!S=Y?^@9LLNO)*8ACA\.TND[@)"V(+
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MTVAK(30)33<NX#%H7J<G^]#*)P;!3O.\ N;_N7?18^^4GH+-^J, LV&6<"U
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M?"CTXF- %5_N8( /DGZ]1EO 9TY=VI7,#Y#4<939PT_(CK%(M9"F]XE;>-^
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M!E!+ 0(4 Q0    ( 'A+*EH)\'F3K@,  &D-   1              "  0
M  !Y;6%B+3(P,C4P,3 V+GAS9%!+ 0(4 Q0    ( 'A+*EJUC%GEA 4  (<^
M   5              "  =T#  !Y;6%B+3(P,C4P,3 V7VQA8BYX;6Q02P$"
M% ,4    " !X2RI:TA*8ZZ0$  "'*   %0              @ &4"0  >6UA
M8BTR,#(U,#$P-E]P<F4N>&UL4$L! A0#%     @ >$LJ6HZ_DQC((@  ;=0
M !0              ( !:PX  'EM86(M,C R-3 Q,#9X.&LN:'1M4$L! A0#
M%     @ >$LJ6B):3K/@%P  =W@  !@              ( !93$  'EM86(M
I,C R-3 Q,#9X97@Y.60Q+FAT;5!+!08     !0 % $T!  ![20     !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>ymab-20250106x8k_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2024"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="ymab-20250106.xsd" xlink:type="simple"/>
    <context id="Duration_1_6_2025_To_1_6_2025_rbdgIz0CSUSvSHbyAAhdRA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001722964</identifier>
        </entity>
        <period>
            <startDate>2025-01-06</startDate>
            <endDate>2025-01-06</endDate>
        </period>
    </context>
    <dei:EntityCentralIndexKey
      contextRef="Duration_1_6_2025_To_1_6_2025_rbdgIz0CSUSvSHbyAAhdRA"
      id="Tc__BPge1uGVEWUsqnr_vfcEQ_2_1">0001722964</dei:EntityCentralIndexKey>
    <dei:AmendmentFlag
      contextRef="Duration_1_6_2025_To_1_6_2025_rbdgIz0CSUSvSHbyAAhdRA"
      id="Tc_49xjKJKJREyvrnlv4PNT0g_3_1">false</dei:AmendmentFlag>
    <dei:DocumentType
      contextRef="Duration_1_6_2025_To_1_6_2025_rbdgIz0CSUSvSHbyAAhdRA"
      id="Narr_Dh87k9XnCkia8ucUDi0Z6w">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate
      contextRef="Duration_1_6_2025_To_1_6_2025_rbdgIz0CSUSvSHbyAAhdRA"
      id="Narr_fBpGrwx4QU-gkh7w6508qg">2025-01-06</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName
      contextRef="Duration_1_6_2025_To_1_6_2025_rbdgIz0CSUSvSHbyAAhdRA"
      id="Narr_Prju1mpuLEudtQNk1tUCRg">Y-MABS THERAPEUTICS, INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="Duration_1_6_2025_To_1_6_2025_rbdgIz0CSUSvSHbyAAhdRA"
      id="Tc_CclIF2HcV0KnM0MBxU1l4A_1_0">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber
      contextRef="Duration_1_6_2025_To_1_6_2025_rbdgIz0CSUSvSHbyAAhdRA"
      id="Tc_ceqIQDdrZESNV5EEZFHe7g_1_2">001-38650</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber
      contextRef="Duration_1_6_2025_To_1_6_2025_rbdgIz0CSUSvSHbyAAhdRA"
      id="Tc_-6ADOGIL10GDtzLXJ5RUTQ_1_4">47-4619612</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="Duration_1_6_2025_To_1_6_2025_rbdgIz0CSUSvSHbyAAhdRA"
      id="Narr_MK-vCMsKl0CJUl4w4dU3BA">230 Park Avenue</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2
      contextRef="Duration_1_6_2025_To_1_6_2025_rbdgIz0CSUSvSHbyAAhdRA"
      id="Narr_yHVVjB7zY0uw_fLsfWyx9g">Suite 3350</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown
      contextRef="Duration_1_6_2025_To_1_6_2025_rbdgIz0CSUSvSHbyAAhdRA"
      id="Narr_va6VGrLWUEOXX7nrgfF7pA">New York</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="Duration_1_6_2025_To_1_6_2025_rbdgIz0CSUSvSHbyAAhdRA"
      id="Narr_A2aFAujcwEa_osyZgVlcCA">NY</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="Duration_1_6_2025_To_1_6_2025_rbdgIz0CSUSvSHbyAAhdRA"
      id="Narr__JanlHeFKUmf6_ikV7tomA">10169</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="Duration_1_6_2025_To_1_6_2025_rbdgIz0CSUSvSHbyAAhdRA"
      id="Narr_zAxq0XqCMkWMZMhgvDc5YA">646</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="Duration_1_6_2025_To_1_6_2025_rbdgIz0CSUSvSHbyAAhdRA"
      id="Narr_MYiWytRkhUKmB1cm0bT_2w">885-8505</dei:LocalPhoneNumber>
    <dei:WrittenCommunications
      contextRef="Duration_1_6_2025_To_1_6_2025_rbdgIz0CSUSvSHbyAAhdRA"
      id="Narr_nC0_AMdcnUi7JaBtBFnKMA">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial
      contextRef="Duration_1_6_2025_To_1_6_2025_rbdgIz0CSUSvSHbyAAhdRA"
      id="Narr_-ajk1hFW3UacR79c_0lXqw">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer
      contextRef="Duration_1_6_2025_To_1_6_2025_rbdgIz0CSUSvSHbyAAhdRA"
      id="Narr_5o2RTj3Md02-JnS4d7r54w">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer
      contextRef="Duration_1_6_2025_To_1_6_2025_rbdgIz0CSUSvSHbyAAhdRA"
      id="Narr_HeXVVG7NwUiM4lEbsABUPg">false</dei:PreCommencementIssuerTenderOffer>
    <dei:Security12bTitle
      contextRef="Duration_1_6_2025_To_1_6_2025_rbdgIz0CSUSvSHbyAAhdRA"
      id="Tc_H3fWjJjYrkCYiDn0_wl0hQ_2_0">Common Stock, $0.0001 par value</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="Duration_1_6_2025_To_1_6_2025_rbdgIz0CSUSvSHbyAAhdRA"
      id="Tc_PobH5ysC0kqpxeyFz0hOAw_2_2">YMAB</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="Duration_1_6_2025_To_1_6_2025_rbdgIz0CSUSvSHbyAAhdRA"
      id="Tc_lSuC_Ton3UewnFYvuOLUeQ_2_4">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityEmergingGrowthCompany
      contextRef="Duration_1_6_2025_To_1_6_2025_rbdgIz0CSUSvSHbyAAhdRA"
      id="Narr_lGJ8q8VFXkCSjbbyrZqvmw">false</dei:EntityEmergingGrowthCompany>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
